Increase in Remdesivir Supply
The creator of COVID-19 treatment remdesivir, Gilead Sciences, has announced last Friday that it has an “ample” supply of the antiviral drug for hospitalized patients by the end of October.
CEO Daniel O’Day said that the recent large-scale trial of remdesivir was “meaningful.”
“They’ll definitely help patients around the world who have the misfortune of entering into the hospital to get better, and I’m really pleased to say that we have ample supply,” O’Day stated.
The trial results revealed that the drug has decreased the time it took for patients to recover by an average of 5 days. Furthermore, patients have a 50% chance of recovering 15 days after the treatment, compared to those who received a placebo.
“These data from a rigorous, double-blind, placebo-controlled trial add to the breadth of evidence from additional randomized clinical trials supporting the use of Veklury as a standard of care for the treatment of COVID-19 in hospitalized patients,” Gilead’s chief medical officer Merdad Parsey revealed.
Increasing Supply To Meet the Demands
According to reports, remdesivir is one of the coronavirus medications used by President Donald Trump. Currently, the medication is used through an IV. However, Gilead announced that they’re working on an inhaled version.
Moreover, the company confirmed that they have invested in increasing the manufacturing “long before we knew whether remdesivir would work.”
“We brought on more than 40 additional manufacturing partners and our teams worked day and night to find ways to shorten the lead time, without compromising on safety or rigor,” O’Day added.
“Supply of Veklury is expected to meet global demand by the end of this month, enabling the purchase of Veklury both to treat patients and to support national stockpiling of the medicine for current and future surges of COVID-19,” the executive confirmed.
Editor’s note on Gilead Announcing Significant Increase in Remdesivir Supply:
This piece is to inform you about Gilead Announcing Its Significant Increase in Supply of COVID-19 Treatment Remdesivir.
For further information about the recent COVID updates, don’t hesitate to send us an email at Outreach@ConsiderTheConsumer.com, find us on Twitter or Facebook, or even connect with us directly on our website! We look forward to hearing from you all.
Similarly, please check out our current list of Class Actions and Class Action Investigations, here.
Interested in articles like these? Become a subscriber below!